Sales and profit grew well above analysts' expectations in the first quarter of this year for the Hungarian pharmaceutical company Richter Gedeon Plc. The firm achieved a consolidated after tax profit of HUF 29.1 billion, which is 34.6% higher than in the same period of the previous year, and its sales revenue increased by 16.3% […]
As a result of the latest development of GlaxoSmithKline (GSK), the operations of its Hungarian factory in Gödöllő, east of Budapest have been extended to manufacture diphtheria and tetanus vaccine components for a new area of application. GlaxoSmithKline was established in 2001 by the merger of GlaxoWellcome, a company with a century-long history, and SmithKline […]
The leading French pharmaceutical company Sanofi is to establish a Center of Excellence in Budapest, the Hungarian Investment Promotion Agency (HIPA) announced. Initially, a hundred people will assist Sanofi subsidiaries in the field of accounting, HR and finance in seven languages, however, the center will be expanded to 350 persons by 2022. Sanofi was founded […]
Hungarian pharmaceutical company Gedeon Richter Plc. said that it launched a biosimilar teriparatide drug called Terrosa® in Europe. The product is approved in adults for the same indications as Eli Lilly’s Forsteo® and is used for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. Terrosa is also used […]
Hungarian pharma firm Gedeon Richter has signed an exclusive license agreement with Hikma Pharmaceuticals Plc. to sell Richter's anti-psychotic drug ‘cariprazine’ in some Middle Eastern and North African (MENA) markets. Under the terms of the agreement, Richter will be responsible for product supply and Hikma will proceed with the registration and commercialization of the product […]
A new molecular biology laboratory of the Hungarian pharmaceutical company Richter Gedeon was inaugurated in Debrecen, E Hungary. The new lab serves the company's objectives of appearing on new markets internationally.
The latest development by the Danish pharmaceutical company Xellia Pharmaceuticals has been completed at its Kõbánya site in Budapest. The laboratory constructed as part of a development of EUR 11 million will operate as a testing centre for active ingredients.
The Hungarian pharmaceutical company Gedeon Richter Plc. has announced that the European Commission has granted marketing authorization to Reagila (cariprazine) a novel antipsychotic for the treatment of schizophrenia in adult patients.
GlaxoSmithKline (GSK) is launching a development worth EUR 57 million in its Gödöllõ plant. Upon completion of the investment, the plant will have expanded activity, producing diphtheria and tetanus vaccine (DT and TT) components for new areas of use.
Hungary’s leading pharmaceutical company, Gedeon Richter Plc., has signed an exclusive license agreement with Recordati to commercialize cariprazine, a novel atypical antipsychotic in Western Europe and in Algeria, Tunisia and Turkey.
Hungary’s largest drugs producer, Gedeon Richter Plc., has announced that it bought out its Chinese partner, obtaining its outstanding 50% stake, further strengthening its presence in China, the Hungarian financial website portfolio.hu reports.
